Modeling the cost and impact of injectable opioid agonist therapy on overdose and overdose deaths

Original research
by
Tse, Wai Chung et al

Release Date

2022

Geography

Australia

Language of Resource

English

Full Text Available

No

Open Access / OK to Reproduce

No

Peer Reviewed

Yes

Objective

We aimed to model whether unsupervised iOAT may be effective in reducing fatal and non–fatal overdose, and estimate the cost per life saved.

Findings/Key points

An implementation scenario with greater unsupervised iOAT compared to supervised iOAT allows for an increased reduction in overdose and overdose deaths per annum at the same cost, with the additional benefit of increased treatment coverage among PWIO.

Design/methods

Decision tree model based on Australian and international parameters for overdose risk in people who inject opioids who are: not on OAT; new/stable to methadone/buprenorphine treatment; on iOAT; or on unsupervised iOAT.

Keywords

Overdose
Evidence base
Policy/Regulatory